Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

NCT00529204 · Terminated

Last updated 2026-05-28

This clinical trial tests whether the medication exenatide can improve liver function and fat metabolism in adults with fatty liver disease and diabetes complications.

Status Terminated Stopped early and will not restart.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 1 person

Who can join Ages 18–70 · all sexes

Timeline Started 2007-10 · est. completion 2010-02

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT00529204 ↗

Description as written by the study sponsor.

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common complications of type 2 diabetes and leading causes of liver disease in the US and Europe. The prevalence of NAFLD and NASH are expected to become a major cause of liver disease related deaths and liver transplantation. Currently, there are no specific therapies that alter the natural history of NAFLD.Preliminary evidence suggests that exenatide (Byetta®) may have several beneficial direct and indirect effects on NAFLD and liver lipid metabolism.

Treatments tested

exenatide also known as BYETTA Drug

Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24

Main thing measured	Reduction in Serum ALT From Baseline to 24 Weeks of Exenatide Therapy
Sponsor	University of California, Davis
Conditions studied	Diabetes Complications, Fatty Liver
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00529204 ↗